Clin Cancer Res: CEACAM7 is an effective target for CAR-T cells in the treatment of pancreatic catheter adenocarcinoma

Pancreatic catheter adenocarcinoma (PDAC) is the fourth most common cause of death associated with solid tumors, with a five-year survival rate of less than 5%.
CEACAM7 (CGM2) is a relatively small study of the CEA family members, the family protein has a variety of functions, common disorders in malignant tumors.
Deepak et al. speculated that CEACAM7 might be an appropriate target for CAR T cell therapy for PDAC, and studied this and developed CEACAM7 targeted CAR T cells to validate this hypothesis.
Deepak et al. determined that CEACAM7 is a member of the CEA family protein, whose expression is limited to the colon and pancreas and is a potential TARGET for PDAC's CAR T cells.
researchers tested the expression of CEACAM7 in PDAC tumor slices and patient-sourced PDAC cells, constructed CAR T cells targeted at CEACAM7, and evaluated the anti-tumor effect of CEACAM7 CAR T cells using in vivo and in vivo models.
CEACAM7 expression in various tissues showed that CEACAM7 was expressed in a large subst group of PDAC tumors, with little or no detection in all the normal tissues tested.
CEACAM7 is also expressed in PDAC progenito cells isolated from patient-sourced tumors, as well as in sub-groups rich in tumor stem cells.
the anti-tumor activity of CAR T cells targeting CEACAM7 targets tumor cells expressed by antigens and slows the growth of patient-sourced heterogeneic transplant tumors.
, the study showed that CEACAM7 was identified as a potential therapeutic target for PDAC, and that CAR T cells targeted at CEACAM7 were constructed and its anti-PDAC efficacy was verified.